Full Breakdown
Prediction Markets Open to FDA Cancer-Drug Approvals, Prompting Industry Alarm
8/6/2026, 10:20:42 AM
New Prediction Markets Target FDA Cancer-Drug Approvals
Betting platforms Kalshi and Polymarket have introduced contracts that let users wager on whether the Food and Drug Administration (FDA) will approve medicines for lung, breast, pancreatic and blood cancers within the current year. Kalshi also plans to add markets on the success of individual drug trials.
How the Markets Operate
Each contract settles based on the FDA’s regulatory decision or the outcome of a clinical trial. Participants place stakes on binary outcomes—approval versus non-approval or trial success versus failure—and receive payouts if their prediction proves correct. The platforms present these markets alongside other financial products, treating regulatory outcomes as tradable events.
Concerns from the Medical Community
Researchers, physicians and patient advocates have warned that public prediction markets could jeopardize the integrity of drug development. They argue that visible betting odds might influence trial participants to withdraw or cause trial administrators to alter conduct, consciously or unconsciously, to align with market expectations. Former FDA commissioner Dr. Robert Califf described the practice as “a breach of scientific conduct,” emphasizing the risk of compromised study results and potential insider-trading violations. The same critics note that eroding public confidence in biotechnology could have long-term repercussions for research funding and patient trust.
Regulatory Response
Emily Hilliard, spokeswoman for the Department of Health and Human Services—the agency that oversees the FDA—stated that agency employees are bound by “stringent ethics requirements.” The statement underscores that current federal ethics rules are intended to prevent conflicts of interest, though it does not specify any pending regulatory action on the prediction markets themselves.
Petition and Public Reaction
A Change.org petition calling for regulators to ban betting on drug development has gathered more than 180 signatures as of the article’s publication. No formal regulatory measures have been announced in response to the petition.
